EW vs MDT
Edwards Lifesciences and Medtronic, both Healthcare
Medtronic is the larger company at $102B against $50B. On trailing earnings MDT is the cheaper of the two at a P/E of 24.6 against 52.2, a gap that is only a bargain if the two are growing at similar rates. Over the past year EW returned +15% against +5.4% for MDT. Ryufin's sector-relative Smart Score puts MDT ahead, 8/10 against 7/10.
| Figure | EW | MDT |
|---|---|---|
| Last close | $90.77 | $92.01 |
| Market cap | $50B | $102B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 52.2 | 24.6 |
| Dividend yield | n/a | 3.1% |
| 1-year return | +15% | +5.4% |
| 5-year return | -19% | -19% |
| Ryufin Smart Scoresector-relative, 1–10 | 7/10 | 8/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Edwards Lifesciences
Revenue of $1.7B in Q2 2026, net income $241M. Its largest reported line is Transcatheter Aortic Valve Replacement, 73% of the disclosed total.
Medtronic
Revenue of $9.8B in Q4 2026, net income $1.2B. Its largest reported line is Total Other Countries Excluding Ireland, 100% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.